AutoICD API

76546-1

Laboratory

Breast cancer 10-year risk of distant recurrence panel by Prosigna

Definition

A 10-year breast cancer distant recurrence risk panel created for the Prosigna™ Breast Cancer Prognostic Gene Signature assay, which is intended for use in postmenopausal women with node-negative (Stage I or II) or node-positive (Stage II), hormone receptor-positive (HR+) breast cancer who have undergone surgery and are to be treated with adjuvant endocrine therapy alone. The panel includes terms for primary tumor size, lymph node status, distant recurrence risk score, and distance recurrence risk classification. The 10-year breast cancer distant recurrence risk score (also referred to as ROR Score or Risk of Recurrence Score) is a numerical score on a scale of 0 -100 that is calculated using a statistical model that includes: 1) the results from a 50-gene expression assay performed on formalin fixed paraffin embedded breast tumor tissue previously diagnosed as invasive carcinoma; 2) proliferation score; and 3) gross tumor size. The calculated score and information about lymph node status are used together to classify the patient into a risk category for distant breast cancer recurrence at 10 years.

LOINC 6-Axis Classification

Component

Breast cancer 10Y risk of distant recurrence panel

Property

-

Time Aspect

Pt

System

^Patient

Scale Type

-

Method Type

Prosigna

Details

Class

PANEL.MOLPATH

Order/Observation

Order

Short Name

Brst ca 10Y risk dist recur Pnl Prosigna

Display Name

Breast cancer 10-year risk of distant recurrence panel Prosigna

Related Names

breast cancerBrst ca10Y risk dist recur PnlMolecular pathologyMOLPATHPAM50PanPanel.molpathPanlPnlPoint in timeProsignaPsoriasis Care Satisfaction questionnaireRandom

Frequently Asked Questions

What is LOINC code 76546-1?

LOINC code 76546-1 identifies "Breast cancer 10-year risk of distant recurrence panel by Prosigna". A 10-year breast cancer distant recurrence risk panel created for the Prosigna™ Breast Cancer Prognostic Gene Signature assay, which is intended for use in postmenopausal women with node-negative (Stage I or II) or node-positive (Stage II), hormone receptor-positive (HR+) breast cancer who have undergone surgery and are to be treated with adjuvant endocrine therapy alone. The panel includes terms for primary tumor size, lymph node status, distant recurrence risk score, and distance recurrence risk classification. The 10-year breast cancer distant recurrence risk score (also referred to as ROR Score or Risk of Recurrence Score) is a numerical score on a scale of 0 -100 that is calculated using a statistical model that includes: 1) the results from a 50-gene expression assay performed on formalin fixed paraffin embedded breast tumor tissue previously diagnosed as invasive carcinoma; 2) proliferation score; and 3) gross tumor size. The calculated score and information about lymph node status are used together to classify the patient into a risk category for distant breast cancer recurrence at 10 years.

What does 76546-1 measure?

This code measures Breast cancer 10Y risk of distant recurrence panel in ^Patient. It belongs to the PANEL.MOLPATH class in the LOINC classification.

What is LOINC?

LOINC (Logical Observation Identifiers Names and Codes) is a universal standard for identifying laboratory and clinical observations. It is maintained by the Regenstrief Institute and used worldwide for health data exchange.